GlycoEra names Andrea Matthews chief business officer

By Public Technologies
  • LifeArc Ventures-backed GlycoEra named Andrea Matthews chief business officer to support its next phase of growth.
  • Matthews was chief business officer at Astria Therapeutics, leading corporate strategy, business development, investor relations, communications, patient advocacy.
  • She previously served as SVP, corporate affairs at Catabasis Pharmaceuticals, held leadership roles at Selventa.
  • GlycoEra cited her role in Astria’s USD 920 million acquisition by BioCryst Pharmaceuticals.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. LifeArc Ventures published the original content used to generate this news brief on September 22, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk